FY 2019 Drug Development Drives FY 2021 User Fees Lower
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.
You may also be interested in...
But the agency chose to fund only a small fraction of them, in part because of its hiring ability, and in part because all those employees would have cost an additional $98.7m in user fee revenue.
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.